[1]
|
Wigner, P., Grębowski, R., Bijak, M., Saluk-Bijak, J. and Szemraj, J. (2021) The Interplay between Oxidative Stress, In-flammation and Angiogenesis in Bladder Cancer Development. International Journal of Molecular Sciences, 22, Article 4483. https://doi.org/10.3390/ijms22094483
|
[2]
|
de Andrade, C.T., Rocha, G.Z., Zamuner, M., Dos Reis, R.B. and Reis, L.O. (2022) Obesity Influence on Bladder Inflammation and Cancer: A Cystitis Model. International Journal of Clinical and Experimental Pathology, 15, 373-379.
|
[3]
|
Ngabire, D. and Kim, G.D. (2017) Autophagy and Inflamma-tory Response in the Tumor Microenvironment. International Journal of Molecular Sciences, 18, Article 2016. https://doi.org/10.3390/ijms18092016
|
[4]
|
Porta, C., Larghi, P., Rimoldi, M., Totaro, M.G., Allavena, P., Manto-vani, A. and Sica, A. (2009) Cellular and Molecular Pathways Linking Inflammation and Cancer. Immunobiology, 214, 761-777.
https://doi.org/10.1016/j.imbio.2009.06.014
|
[5]
|
Nesi, G., Nobili, S., Cai, T., Caini, S. and Santi, R. (2015) Chronic Inflammation in Urothelial Bladder Cancer. Virchows Archiv, 467, 623-633. https://doi.org/10.1007/s00428-015-1820-x
|
[6]
|
Kuper, H., Adami, H.O. and Trichopoulos, D. (2000) Infections as a Major Preventable Cause of Human Cancer. Journal of Internal Medicine, 248, 171-183. https://doi.org/10.1046/j.1365-2796.2000.00742.x
|
[7]
|
Lobo, N., Afferi, L., Moschini, M., Mostafid, H., Porten, S., Psutka, S.P., Gupta, S., Smith, A.B., Williams, S.B. and Lotan, Y. (2022) Epidemiology, Screening, and Prevention of Bladder Cancer. European Urology Oncology, 5, 628-639.
https://doi.org/10.1016/j.euo.2022.10.003
|
[8]
|
Jubber, I., Ong, S., Bukavina, L., Black, P.C., Compérat, E., Kamat, A.M., Kiemeney, L., Lawrentschuk, N., Lerner, S.P., Meeks, J.J., Moch, H., Necchi, A., Panebianco, V., Sridhar, S.S., Znaor, A., Catto, J.W.F. and Cumberbatch, M.G. (2023) Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. European Urology, 84, 176-190.
https://doi.org/10.1016/j.eururo.2023.03.029
|
[9]
|
Hannan, T.J., Mysorekar, I.U., Hung, C.S., Isaacson-Schmid, M.L. and Hultgren, S.J. (2010) Early Severe Inflammatory Responses to Uropathogenic E. Coli Predispose to Chronic and Recurrent Urinary Tract Infection. PLOS Pathogens, 6, e1001042. https://doi.org/10.1371/journal.ppat.1001042
|
[10]
|
Abol-Enein, H. (2008) Infection: Is It a Cause of Bladder Cancer? Scandinavian Journal of Urology and Nephrology, 42, 79-84. https://doi.org/10.1080/03008880802325309
|
[11]
|
Botelho, M.C., Oliveira, P.A., Lopes, C., Correia da Costa, J.M. and Machado, J.C. (2011) Urothelial Dysplasia and Inflammation Induced by Schistosoma haematobium Total Antigen Instillation in Mice Normal Urothelium. Urologic Oncology: Seminars and Original Investigations, 29, 809-814. https://doi.org/10.1016/j.urolonc.2009.09.017
|
[12]
|
Botelho, M.C., Machado, J.C. and da Costa, J.M. (2010) Schistosoma haematobium and Bladder Cancer: What Lies Beneath? Virulence, 1, 84-87. https://doi.org/10.4161/viru.1.2.10487
|
[13]
|
Ohshima, H., Tatemichi, M. and Sawa, T. (2003) Chemical Basis of In-flammation-Induced Carcinogenesis. Archives of Biochemistry and Biophysics, 417, 3-11. https://doi.org/10.1016/S0003-9861(03)00283-2
|
[14]
|
Kantor, A.F., Hartge, P., Hoover, R.N., Narayana, A.S., Sul-livan, J.W. and Fraumeni Jr., J.F. (1984) Urinary Tract Infection and Risk of Bladder Cancer. American Journal of Epi-demiology, 119, 510-515.
https://doi.org/10.1093/oxfordjournals.aje.a113768
|
[15]
|
Jiang, X., Castelao, J.E., Groshen, S., Cortessis, V.K., Shibata, D., Conti, D.V., Yuan, J.M., Pike, M.C. and Gago-Dominguez, M. (2009) Urinary Tract Infections and Re-duced Risk of Bladder Cancer in Los Angeles. British Journal of Cancer, 100, 834-839. https://doi.org/10.1038/sj.bjc.6604889
|
[16]
|
Wei, L., Gravitt, P.E., Song, H., Maldonado, A.M. and Ozbun, M.A. (2009) Nitric Oxide Induces Early Viral Transcription Coincident with Increased DNA Damage and Mutation Rates in Human Papillomavirus-Infected Cells. Cancer Research, 69, 4878-4884. https://doi.org/10.1158/0008-5472.CAN-08-4695
|
[17]
|
Guma, S., Maglantay, R., Lau, R., Wieczorek, R., Melamed, J., Deng, F.M., Zhou, M., Makarov, D., Lee, P., Pincus, M.R., et al. (2016) Papillary Urothelial Carcinoma with Squa-mous Differentiation in Association with Human Papilloma Virus: Case Report and Literature Review. American Journal of Clinical and Experimental Urology, 4, 12-16.
|
[18]
|
Groah, S.L., Weitzenkamp, D.A., Lammertse, D.P., Whiteneck, G.G., Lezotte, D.C. and Hamman, R.F. (2002) Excess Risk of Bladder Cancer in Spinal cord Injury: Evidence for an Association between Indwelling Catheter Use and Bladder Cancer. Archives of Physical Medicine and Rehabilitation, 83, 346-351.
https://doi.org/10.1053/apmr.2002.29653
|
[19]
|
Song, J., Li, A., Qian, Y., Liu, B., Lv, L., Ye, D., Sun, X. and Mao, Y. (2022) Genetically Predicted Circulating Levels of Cytokines and the Risk of Cancer. Frontiers in Immunology, 13, Article 886144.
https://doi.org/10.3389/fimmu.2022.886144
|
[20]
|
Song, S., Chen, H., Dou, X., Wang, K., Yan, J. and Yu, C. (2022) The Prognostic Value of before Treatment Neutrophil-to-Lymphocyte Ratio in Nasopharyngeal Carcinoma. European Archives of Oto-Rhino-Laryngology, 279, 2485-2492. https://doi.org/10.1007/s00405-021-07070-3
|
[21]
|
Shau, H.Y. and Kim, A. (1988) Suppression of Lymphokine-Activated Killer Induction by Neutrophils. The Journal of Immu-nology, 141, 4395-4402. https://doi.org/10.4049/jimmunol.141.12.4395
|
[22]
|
Bingle, L., Brown, N.J. and Lewis, C.E. (2002) The Role of Tumour-Associated Macrophages in Tumour Progression: Implications for New Anticancer Therapies. The Journal of Pathology, 196, 254-265.
https://doi.org/10.1002/path.1027
|
[23]
|
Yang, H., Kim, C., Kim, M.J., Schwendener, R.A., Alitalo, K., Heston, W., Kim, I., Kim, W.J. and Koh, G.Y. (2011) Soluble Vascular Endothelial Growth Factor Receptor-3 Suppresses Lymphan-giogenesis and Lymphatic Metastasis in Bladder Cancer. Molecular Cancer, 10, Article No. 36. https://doi.org/10.1186/1476-4598-10-36
|
[24]
|
Ayari, C., LaRue, H., Hovington, H., Caron, A., Bergeron, A., Têtu, B., Fradet, V. and Fradet, Y. (2013) High Level of Mature Tumor-Infiltrating Dendritic Cells Predicts Progression to Muscle Invasion in Bladder Cancer. Human Pathology, 44, 1630-1637. https://doi.org/10.1016/j.humpath.2013.01.014
|
[25]
|
Eruslanov, E., Daurkin, I., Vieweg, J., Daaka, Y. and Kusmartsev, S. (2011) Aberrant PGE2 Metabolism in Bladder Tumor Microenvironment Promotes Immunosuppressive Phenotype of Tumor-Infiltrating Myeloid Cells. International Immunopharmacology, 11, 848-855. https://doi.org/10.1016/j.intimp.2011.01.033
|
[26]
|
Fridlender, Z.G., Sun, J., Singhal, S., Kapoor, V., Cheng, G., Suzuki, E. and Albelda, S.M. (2010) Chemotherapy Delivered after Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-Mediated Mechanisms. Molecular Therapy, 18, 1947-1959. https://doi.org/10.1038/mt.2010.159
|
[27]
|
Winerdal, M.E., Marits, P., Winerdal, M., Hasan, M., Rosenblatt, R., Tolf, A., Selling, K., Sherif, A. and Winqvist, O. (2011) FOXP3 and Survival in Urinary Bladder Cancer. BJU International, 108, 1672-1678.
https://doi.org/10.1111/j.1464-410X.2010.10020.x
|
[28]
|
Sharma, P., Shen, Y., Wen, S., Yamada, S., Jungbluth, A.A., Gnjatic, S., Bajorin, D.F., Reuter, V.E., Herr, H., Old, L.J., et al. (2007) CD8 Tumor-Infiltrating Lymphocytes Are Predictive of Survival in Muscle-Invasive Urothelial Carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 104, 3967-3972.
https://doi.org/10.1073/pnas.0611618104
|
[29]
|
Chi, L.J., Lu, H.T., Li, G.L., Wang, X.M., Su, Y., Xu, W.H. and Shen, B.Z. (2010) Involvement of T Helper Type 17 and Regulatory T Cell Activity in Tumour Immunology of Bladder Carcinoma. Clinical and Experimental Immunology, 161, 480-489. https://doi.org/10.1111/j.1365-2249.2010.04215.x
|
[30]
|
Pignot, G., Bieche, I., Vacher, S., Güet, C., Vieillefond, A., Debré, B., Lidereau, R. and Amsellem-Ouazana, D. (2009) Large-Scale Real-Time Reverse Transcription-PCR Approach of Angiogenic Pathways in Human Transitional Cell Carcinoma of the Bladder: Identification of VEGFA as a Major In-dependent Prognostic Marker. European Urology, 56, 678-689. https://doi.org/10.1016/j.eururo.2008.05.027
|
[31]
|
Reis, S.T., Leite, K.R., Piovesan, L.F., Pontes-Junior, J., Viana, N.I., Abe, D.K., Crippa, A., Moura, C.M., Adonias, S.P., Srougi, M., et al. (2012) Increased Expression of MMP-9 and IL-8 Are Correlated with Poor Prognosis of Bladder Cancer. BMC Urology, 12, Article No. 18. https://doi.org/10.1186/1471-2490-12-18
|
[32]
|
Lee, S.J., Park, S.S., Lee, U.S., Kim, W.J. and Moon, S.K. (2008) Signaling Pathway for TNF-α-Induced MMP-9 Expression: Mediation through p38 MAP Kinase, and Inhibition by An-ti-Cancer Molecule Magnolol in Human Urinary Bladder Cancer 5637 Cells. International Immunopharmacology, 8, 1821-1826.
https://doi.org/10.1016/j.intimp.2008.08.018
|
[33]
|
Miyake, M., Lawton, A., Goodison, S., Urquidi, V., Gomes-Giacoia, E., Zhang, G., Ross, S., Kim, J. and Rosser, C.J. (2013) Chemokine (C-X-C) Ligand 1 (CXCL1) Pro-tein Expression Is Increased in Aggressive Bladder Cancers. BMC Cancer, 13, Article No. 322. https://doi.org/10.1186/1471-2407-13-322
|
[34]
|
Murai, R., Itoh, Y., Kageyama, S., Nakayama, M., Ishigaki, H., Teramoto, K., Narita, M., Yoshida, T., Tomita, K., Kobayashi, K.I., et al. (2018) Prediction of Intravesical Recurrence of Non-Muscle-Invasive Bladder Cancer by Evaluation of Intratumoral Foxp3+ T Cells in the Primary Transurethral Resec-tion of Bladder Tumor Specimens. PLOS ONE, 13, e0204745. https://doi.org/10.1371/journal.pone.0204745
|
[35]
|
Margulis, V., Shariat, S.F., Ashfaq, R., Thompson, M., Sagalowsky, A.I., Hsieh, J.T. and Lotan, Y. (2007) Expression of Cyclooxygenase-2 in Normal Urothelium, and Super-ficial and Advanced Transitional Cell Carcinoma of Bladder. Journal of Urology, 177, 1163-1168. https://doi.org/10.1016/j.juro.2006.10.033
|
[36]
|
Tomlinson, D.C., Baxter, E.W., Loadman, P.M., Hull, M.A. and Knowles, M.A. (2012) FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCγ/COX-2-Mediated Mechanisms. PLOS ONE, 7, e38972.
https://doi.org/10.1371/journal.pone.0038972
|
[37]
|
Wheeler, M.A., Hausladen, D.A., Yoon, J.H. and Weiss, R.M. (2002) Prostaglandin E2 Production and Cyclooxygenase-2 Induction in Human Urinary Tract Infections and Bladder Cancer. Journal of Urology, 168, 1568-1573.
https://doi.org/10.1016/S0022-5347(05)64522-3
|
[38]
|
Von der Emde, L., Goltz, D., Latz, S., Müller, S.C., Kristi-ansen, G., Ellinger, J. and Syring, I. (2014) Prostaglandin Receptors EP1-4 as a Potential Marker for Clinical Outcome in Urothelial Bladder Cancer. American Journal of Cancer Research, 4, 952-962.
|
[39]
|
Ehsan, A., Sommer, F., Schmidt, A., Klotz, T., Koslowski, J., Niggemann, S., Jacobs, G., Engelmann, U., Addicks, K. and Bloch, W. (2002) Nitric Oxide Pathways in Human Bladder Carcinoma. The Distribution of Nitric Oxide Synthases, Soluble Guanylyl Cyclase, Cyclic Guanosine Monophosphate, and Nitrotyrosine. Cancer, 95, 2293-2301.
https://doi.org/10.1002/cncr.10942
|
[40]
|
Gecit, I., Aslan, M., Gunes, M., Pirincci, N., Esen, R., Demir, H. and Ceylan, K. (2012) Serum Prolidase Activity, Oxidative Stress, and Nitric Oxide Levels in Patients with Bladder Cancer. Journal of Cancer Research and Clinical Oncology, 138, 739-743. https://doi.org/10.1007/s00432-011-1136-4
|
[41]
|
Zappavigna, S., Cossu, A.M., Grimaldi, A., Bocchetti, M., Ferra-ro, G.A., Nicoletti, G.F., Filosa, R. and Caraglia, M. (2020) Anti-Inflammatory Drugs as Anticancer Agents. Interna-tional Journal of Molecular Sciences, 21, Article 2605.
https://doi.org/10.3390/ijms21072605
|
[42]
|
Xu, X.C. (2002) COX-2 Inhibitors in Cancer Treatment and Prevention, a Recent Development. Anti-Cancer Drugs, 13, 127-137. https://doi.org/10.1097/00001813-200202000-00003
|
[43]
|
Greenhough, A., Smartt, H.J., Moore, A.E., Roberts, H.R., Williams, A.C., Paraskeva, C. and Kaidi, A. (2009) The COX-2/PGE2 Pathway: Key Roles in the Hallmarks of Cancer and Adaptation to the Tumour Microenvironment. Carcinogenesis, 30, 377-386. https://doi.org/10.1093/carcin/bgp014
|
[44]
|
Dhawan, D., Craig, B.A., Cheng, L., Snyder, P.W., Mohammed, S.I., Stewart, J.C., Zheng, R., Loman, R.A., Foster, R.S. and Knapp, D.W. (2010) Effects of Short-Term Celecoxib Treatment in Patients with Invasive Transitional Cell Carcinoma of the Urinary Bladder. Molecular Cancer Therapeutics, 9, 1371-1377.
https://doi.org/10.1158/1535-7163.MCT-10-0049
|
[45]
|
Sabichi, A.L., Lee, J.J., Grossman, H.B., Liu, S., Richmond, E., Czerniak, B.A., De la Cerda, J., Eagle, C., Viner, J.L., Palmer, J.L., et al. (2011) A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer. Cancer Prevention Research, 4, 1580-1589. https://doi.org/10.1158/1940-6207.CAPR-11-0036
|
[46]
|
Rosser, C.J., Nix, J., Ferguson, L., Hernandez, L. and Wong, H.C. (2018) Phase Ib Trial of ALT-803, an IL-15 Superagonist, plus BCG for the Treatment of BCG-Naive Pa-tients with Non-Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 36, 510. https://doi.org/10.1200/JCO.2018.36.6_suppl.510
|
[47]
|
Sonpavde, G., Rosser, C.J., Pan, C., Parikh, R.A., Nix, J., Gingrich, J.R., Hernandez, L., Huang, B. and Wong, H.C. (2016) Phase I Trial of ALT-801, a First-in-Class T-Cell Re-ceptor (TCR)-Interleukin (IL)-2 Fusion Molecule, plus Gemcitabine (G) for Bacillus Calmette Guerin (BCG)-Resistant Non-Muscle-Invasive Bladder Cancer (NMIBC). Journal of Clinical Oncology, 34, 451-451. https://doi.org/10.1200/jco.2016.34.2_suppl.451
|